Understanding EU Guidance on First-in-Human Clinical Trials

First-in-human (FIH) studies represent the critical transition from preclinical to clinical development. They mark the first administration of an investigational medicinal product (IMP) to humans, usually healthy volunteers, but sometimes patients in the case of oncology or rare diseases. In the European Union (EU), the regulatory framework for FIH studies has evolved significantly following past safety incidents, most notably the TGN1412 trial in 2006 in the United Kingdom, which underscored the importance of stringent safety protocols. Today, EU FIH trials are governed by the EU Clinical Trial Regulation (CTR) 536/2014, EMA’s 2017 Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials, and Good Clinical Practice (GCP) standards.

This article provides a comprehensive overview of EU requirements for FIH trials, focusing on safety measures, trial design, regulatory submissions, and best practices sponsors must follow to ensure compliance and participant safety.

Background and Regulatory Framework

Lessons from the TGN1412 Incident

The TGN1412 trial in 2006 involved a monoclonal antibody that caused life-threatening cytokine storms in six healthy volunteers during a Phase I study. The event led EU regulators to strengthen guidelines, introducing stricter rules for dose calculation, risk assessment, and subject monitoring in FIH trials.

EMA Guideline (2017)

The EMA issued its revised guidance in 2017, “Guideline on Strategies to Identify and Mitigate Risks for First-in-Human and Early Clinical Trials,” focusing on:

• Integrated risk assessment across quality, non-clinical, and clinical data
• Safe starting dose determination
• Sentinel dosing strategies
• Stopping rules and dose escalation protocols

EU CTR 536/2014

The CTR harmonizes the submission, assessment, and oversight process for all trials, including FIH studies. Sponsors must submit clinical trial applications (CTAs) through the Clinical Trials Information System (CTIS), ensuring transparency and Member State collaboration.

Core Clinical Trial Insights: EU First-in-Human Studies

1. Risk Assessment and Mitigation

FIH trials must be based on a holistic risk assessment integrating:

• Pharmacology – mechanism of action, target expression, relevance of animal models
• Toxicology – no observed adverse effect level (NOAEL), minimal anticipated biological effect level (MABEL)
• Pharmaceutical quality – formulation, stability, and impurity profile

Risk mitigation includes close subject monitoring, predefined stopping rules, and rapid medical intervention capabilities.

2. Starting Dose Selection

Unlike traditional NOAEL-based methods, the EMA encourages the use of MABEL for high-risk biologics and advanced therapies. Dose escalation must proceed cautiously, often with sentinel subjects receiving the dose before others in the cohort.

3. Study Design and Escalation Strategies

FIH studies may include:

• Single ascending dose (SAD) studies
• Multiple ascending dose (MAD) studies
• Food-effect and drug-drug interaction sub-studies

Sentinel dosing is mandatory in high-risk studies. Adaptive designs allow flexibility but require predefined statistical and safety boundaries.

4. Participant Selection

Healthy volunteers are typically chosen, except for oncology or rare disease drugs where patient trials may be justified. Volunteers must undergo rigorous screening, including immunological and biomarker profiling for biologics.

5. Site and Investigator Requirements

Sites conducting FIH trials must have:

• Intensive care facilities available onsite or nearby
• Emergency response teams trained in cytokine release syndrome
• Specialist investigators with experience in Phase I safety monitoring

6. Safety Monitoring and Pharmacovigilance

Real-time safety monitoring, including cytokine panels, biomarkers, and frequent clinical labs, is mandatory. Sponsors must report suspected unexpected serious adverse reactions (SUSARs) to the EudraVigilance Clinical Trial Module (EVCTM).

7. Submissions via CTIS

FIH CTAs must include:

• Investigator’s Brochure (IB)
• Investigational Medicinal Product Dossier (IMPD)
• Protocol with detailed dose escalation plan
• Risk mitigation measures

All documentation is assessed in Part I (scientific data) and Part II (ethics and local feasibility) of the CTR review process.

Best Practices & Preventive Measures

• Engage early with EMA or NCAs for scientific advice on dose calculation and risk mitigation
• Use conservative escalation protocols, especially with biologics or novel modalities
• Train staff in early recognition of adverse immune reactions
• Develop robust emergency response procedures
• Maintain clear communication between sponsors, investigators, and regulators

Scientific and Regulatory Evidence

• Regulation (EU) No 536/2014
• EMA Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Trials (2017)
• ICH M3(R2) on Nonclinical Safety Studies
• ICH E6(R2) – Good Clinical Practice
• EMA Reflection Paper on Risk-Based Trial Design

Special Considerations

Special populations such as pediatrics and geriatrics are rarely included in FIH trials. However, advanced therapies (ATMPs), gene therapies, and immuno-oncology products require additional safeguards, such as long-term follow-up and immunogenicity monitoring. Trials involving high-risk biologics often require staggered dosing and hospital-based monitoring facilities.

When Sponsors Should Seek Regulatory Advice

• Before selecting starting dose methodologies (NOAEL vs. MABEL)
• When designing adaptive escalation protocols
• Prior to initiating trials involving high-risk modalities (e.g., monoclonal antibodies, ATMPs)
• In case of uncertainty about stopping rules or risk thresholds
• When choosing between healthy volunteer vs. patient populations for early studies

FAQs

1. What is the primary objective of FIH trials?

To evaluate initial safety, tolerability, pharmacokinetics, and sometimes pharmacodynamics of a new investigational product in humans.

2. How is the starting dose determined in EU FIH trials?

Based on NOAEL or MABEL, with MABEL preferred for biologics or high-risk products. Conservative approaches are encouraged.

3. Are sentinel subjects required in all EU FIH studies?

No, but sentinel dosing is mandatory in high-risk studies or those involving novel mechanisms of action.

4. Can patients be enrolled in FIH trials?

Yes, particularly in oncology or rare diseases, when the investigational product is unsuitable for healthy volunteers.

5. What are common inspection findings in EU FIH studies?

Findings often relate to inadequate risk mitigation documentation, deviations from dose escalation plans, or insufficient emergency preparedness.

6. How long is the regulatory review timeline for FIH trials?

Typically 60 days under CTR 536/2014, including both Part I (scientific) and Part II (ethics) reviews, though extensions may occur.

7. Are FIH results made public?

Yes. Under CTR 536/2014, results must be submitted to CTIS, including lay summaries for public transparency.

Conclusion

First-in-human trials in the EU are governed by rigorous guidelines to safeguard participants and ensure data integrity. EMA’s 2017 guidance, coupled with CTR 536/2014 and GCP principles, establishes a harmonized, risk-based framework. Sponsors conducting FIH trials must embrace comprehensive risk assessments, careful dose escalation, and robust safety monitoring. By adhering to regulatory expectations and applying best practices, FIH trials can progress smoothly, building the foundation for later clinical development phases.